BR112016017496A2 - Composição para acelerar a penetração através da pele, preparação para administração transdérmica e preparação de emplastro de pele - Google Patents

Composição para acelerar a penetração através da pele, preparação para administração transdérmica e preparação de emplastro de pele

Info

Publication number
BR112016017496A2
BR112016017496A2 BR112016017496A BR112016017496A BR112016017496A2 BR 112016017496 A2 BR112016017496 A2 BR 112016017496A2 BR 112016017496 A BR112016017496 A BR 112016017496A BR 112016017496 A BR112016017496 A BR 112016017496A BR 112016017496 A2 BR112016017496 A2 BR 112016017496A2
Authority
BR
Brazil
Prior art keywords
skin
preparation
composition
penetration
transdermal administration
Prior art date
Application number
BR112016017496A
Other languages
English (en)
Inventor
Maeda Yoshiki
Matsushita Kyohei
Li Wenjing
Okubo Katsuyuki
Hori Mitsuhiko
Original Assignee
Nitto Denko Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nitto Denko Corp filed Critical Nitto Denko Corp
Publication of BR112016017496A2 publication Critical patent/BR112016017496A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration

Abstract

COMPOSIÇÃO PARA ACELERAR A PENETRAÇÃO ATRAVÉS DA PELE, PREPARAÇÃO PARA ADMINISTRAÇÃO TRANSDÉRMICA E PREPARAÇÃO DE EMPLASTRO DE PELE. Trata-se de uma composição para acelerar a penetração através da pele, que pode melhorar significativamente a penetração de um medicamento através da pele sem exigir a conformação do medicamento em uma estrutura particulada ou semelhante e sem causar o dano de tecidos dérmicos. Também é fornecida uma preparação para administração transdérmica e uma preparação de emplastro de pele, em que cada uma contém a composição para acelerar a penetração através da pele. Também é fornecida uma composição para acelerar a penetração através da pele, que contém um composto flavonoide e pode ser usada para acelerar a penetração de um medicamento através da pele.
BR112016017496A 2014-01-29 2015-01-28 Composição para acelerar a penetração através da pele, preparação para administração transdérmica e preparação de emplastro de pele BR112016017496A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014014539 2014-01-29
PCT/JP2015/052388 WO2015115495A1 (ja) 2014-01-29 2015-01-28 皮膚透過促進組成物、経皮投与製剤及び貼付製剤

Publications (1)

Publication Number Publication Date
BR112016017496A2 true BR112016017496A2 (pt) 2017-08-08

Family

ID=53757068

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016017496A BR112016017496A2 (pt) 2014-01-29 2015-01-28 Composição para acelerar a penetração através da pele, preparação para administração transdérmica e preparação de emplastro de pele

Country Status (9)

Country Link
US (1) US20170000751A1 (pt)
EP (1) EP3100744A4 (pt)
JP (1) JP2015163606A (pt)
KR (1) KR20160106761A (pt)
CN (1) CN105939729A (pt)
BR (1) BR112016017496A2 (pt)
CA (1) CA2937526A1 (pt)
RU (1) RU2016134905A (pt)
WO (1) WO2015115495A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105380929A (zh) * 2015-11-23 2016-03-09 蚌埠丰原涂山制药有限公司 一种含洛索洛芬钠的药物组合物及其制备方法
KR102081217B1 (ko) * 2017-09-13 2020-02-25 연세대학교 산학협력단 네프린 억제제를 유효성분으로 포함하는 피부 투과 촉진용 조성물
CN111135087A (zh) * 2020-01-09 2020-05-12 范小玲 一种溶剂型透皮贴的工业化制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5936611A (ja) * 1982-08-26 1984-02-28 Nitto Electric Ind Co Ltd 粘着性貼付製剤
JPS5955822A (ja) * 1982-09-24 1984-03-31 Nitto Electric Ind Co Ltd 粘着性貼付製剤用膏体
JPS6137304A (ja) 1984-07-31 1986-02-22 Nippon Steel Corp 傾斜ロ−ル圧延機
JPH0429934A (ja) * 1990-05-28 1992-01-31 Seiichi Umeda いちょう葉抽出エキスを含有する外用組成物
JPH10139690A (ja) * 1996-11-02 1998-05-26 Shinichi Konuma 経皮吸収促進剤
JP4073517B2 (ja) 1997-04-07 2008-04-09 久光製薬株式会社 経皮吸収貼付剤用粘着剤及び経皮吸収貼付剤
US20030175333A1 (en) * 2002-03-06 2003-09-18 Adi Shefer Invisible patch for the controlled delivery of cosmetic, dermatological, and pharmaceutical active ingredients onto the skin
US7241456B2 (en) * 2002-10-25 2007-07-10 Australian Importers Ltd. Formulations for topical delivery of bioactive substances and methods for their use
JP4027850B2 (ja) * 2003-06-20 2007-12-26 ポーラ化成工業株式会社 経皮吸収促進化粧料
US8016811B2 (en) 2003-10-24 2011-09-13 Altea Therapeutics Corporation Method for transdermal delivery of permeant substances
EP1867323A1 (en) * 2006-06-13 2007-12-19 Farmatron Ltd. Pharmaceutical compositions with biological barriers permeation enhancing properties
KR101408454B1 (ko) * 2006-12-01 2014-06-17 닛토덴코 가부시키가이샤 도네페질 함유 접착 제제의 착색을 억제하는 방법 및 도네페질의 친척 물질의 생성량을 감소시키는 방법
JP5224770B2 (ja) 2007-03-19 2013-07-03 金印株式会社 コラーゲン産生促進剤、促進方法、香粧品、飲食品および医薬品
US9889098B2 (en) * 2009-10-22 2018-02-13 Vizuri Health Sciences Llc Methods of making and using compositions comprising flavonoids
JP6105475B2 (ja) * 2010-10-22 2017-03-29 ヴィズリ・ヘルス・サイエンスィズ・エルエルシー 可溶性の乏しい化合物の可溶性を増大させる方法ならびにそのような化合物の配合物を作る、および用いる方法
JP2012206979A (ja) 2011-03-30 2012-10-25 Ssp Co Ltd 経皮投与用医薬組成物
JP5856424B2 (ja) 2011-10-05 2016-02-09 祐徳薬品工業株式会社 ロチゴチン含有経皮吸収型貼付剤

Also Published As

Publication number Publication date
CN105939729A (zh) 2016-09-14
KR20160106761A (ko) 2016-09-12
EP3100744A1 (en) 2016-12-07
WO2015115495A1 (ja) 2015-08-06
JP2015163606A (ja) 2015-09-10
RU2016134905A (ru) 2018-03-05
EP3100744A4 (en) 2017-08-30
US20170000751A1 (en) 2017-01-05
CA2937526A1 (en) 2015-08-06

Similar Documents

Publication Publication Date Title
IL264413B (en) Preparations containing fibers obtained electrohydrodynamically for delivering specific doses of active substance to the skin or mucous membrane
CO2017001493A2 (es) Kits que comprenden inhibidores tigit y agentes anticáncer
BR112017005693A2 (pt) método para tratar e/ou prevenir uma doença hepática, e, composição farmacêutica.
GT201500011A (es) Ácidos 5-aminotetrahidroquinolin-2-carboxílicos novedosos y su uso
BR112015008447A2 (pt) métodos para tratar câncer
BR112015023203A8 (pt) métodos para tratamento de câncer, método para aumentar a eficiência de um tratamento de câncer, método para retardar e/ou prevenir o desenvolvimento de câncer, método para tratar um indivíduo com câncer, método para aumentar a sensibilidade para um agente de terapia para câncer, método para estender um período de sensibilidade e método para estender a duração da resposta para uma terapia para câncer.
CL2014001865A1 (es) Compuestos derivados de fosfatos; procedimiento de preparacion; composiciones farmaceuticas que los contienen y uso en el tratamiento del cancer.
EA201692334A1 (ru) Кортикостероидные композиции для местного применения
BR112016000335A8 (pt) método de tratamento da rosácea papulopustular, de tratamento de lesões inflamatórias da rosácea papulopustular e uso de uma composição farmacêutica
MX2017004772A (es) Composiciones y métodos para la administración fisiológica utilizando cannabidiol.
CL2015000039A1 (es) Derivados estra-1,3,5(10),16-tetraeno-3-sustituidos, preparaciones farmacéuticas que los comprenden y su uso en la preparación de medicamentos para tratar la endometriosis.
BR112017006113A2 (pt) combinações sinérgicas de auristatina
CL2015001085A1 (es) Formulacion de liberación prolongada que comprende oprozomib y ademas uno o mas polimeros farmaceuticamente aceptables; metodo de preparacion de la formulacion; metodo para tratar cancer.
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
TW201613578A (en) Pharmaceutical combinations
BR112016029012A2 (pt) método de tratamento de câncer de pulmão de células não pequenas e/ou câncer de pulmão de células pequenas usando compostos de tienotriazolodiazepina
BR112018002520A2 (pt) Agonistas de tlr4 e composições dos mesmos e seuuso no tratamento de câncer
CR20160529A (es) Composiciones farmacéuticas para tratar enfermedades infecciosas
BR112016015997A2 (pt) ?composições farmacêuticas que compreendem 15- hepe e métodos para tratar asma e distúrbios pulmonares com o uso das mesmas?
BR112016017496A2 (pt) Composição para acelerar a penetração através da pele, preparação para administração transdérmica e preparação de emplastro de pele
CL2017000884A1 (es) Composición farmacéutica para usarse en el tratamiento o la prevención de deficiencias de vitaminas y minerales en pacientes que han sido sometidos a cirugía de derivación gástrica
BR112014024033A8 (pt) Formulação vesicular, método para o tratamento da rosácea e uso de um ou mais fosfo, sulfolipídios e surfactantes
BR112017014552A2 (pt) ?análogo de calcitonina, e, método para produzir uma diminuição nos triglicerídeos no fígado/redução de acúmulo de gordura no fígado?
CO2018004665A2 (es) Compuestos oxadiazoespíricos
BR112016016700A2 (pt) Composição para acelerar a penetração através da pele, preparação para administração transdérmica, e preparação de emplastro de pele

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]